Gemtuzumab Ozogamicin is a promising post-remission therapy for acute myeloid leukemia.
El Kinge
Abdul Rahman
AR
Hatoum
Hassan A
HA
Mahfouz
Rami A
RA
Otrock
Zaher K
ZK
Jabbour
Elias
E
Kantarjian
Hagop
H
Bazarbachi
Ali
A
D000617:Aminoglycosides / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D005260:Female; D000079982:Gemtuzumab; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy* / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy*
D000617:Aminoglycosides; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D000079982:Gemtuzumab